Spots Global Cancer Trial Database for Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
Official Title: A Phase I, Open-Label, Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD0530 in Combination With Carboplatin and Paclitaxel Chemotherapy in Japanese Patients With Advanced Solid Malignancies
Study ID: NCT01000896
Study Description
Brief Summary: The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelial ovarian cancer.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Matsuyama, Ehime, Japan
Research Site, Fukuoka, , Japan
Contact Details
Name: Mary Stuart
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: Takashi Seto, MD, PhD
Affiliation: National Hospital Organisation Kyushu Cancer Centre
Role: PRINCIPAL_INVESTIGATOR
Name: Naoyuki Nogami, MD
Affiliation: National Hospital Organisation Shikoku Cancer Centre
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
